Kedudukan dalam Saham
#40526
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and... BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Perubahan (1 tahun)
-21.82%
Perdagangan BioLineRx Ltd. (BLRX)
Harga BLRX dengan permodalan pasaran b
Modal pasaran bagi BioLineRx Ltd.(BLRX)
Modal Pasaran: $126.82K
Sehingga August 2026, BioLineRx Ltd. mempunyai modal pasaran sebanyak $126.82K. Ini menjadikan BioLineRx Ltd. syarikat ke-40526th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran BioLineRx Ltd. dari 2007 hingga 2026
BLRX berbanding dengan 5 teratas yang paling popular stocks
| Harga BLRX |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.466T
|
+4,309,898,327.99%
|
|
|
|
|
$4.455T
|
+3,512,637,232.91%
|
|
|
|
|
$4.171T
|
+3,289,349,919.50%
|
|
|
|
|
$3.686T
|
+2,906,571,152.00%
|
|
|
|
|
$2.864T
|
+2,258,126,551.15%
|
